BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feld JJ, Ward JW. Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. Hepatol Commun 2021;5:911-22. [PMID: 34141979 DOI: 10.1002/hep4.1731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Prentoe J, Janitzek CM, Velázquez-moctezuma R, Soerensen A, Jørgensen T, Clemmensen S, Soroka V, Thrane S, Theander T, Nielsen MA, Salanti A, Bukh J, Sander AF. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers. npj Vaccines 2022;7:148. [DOI: 10.1038/s41541-022-00570-1] [Reference Citation Analysis]
2 Guerra-Veloz MF, Han K, Oakes K, Robertson D, Mohamed A, Cannon M, Barnabas A, Shah S, Halford R, Dusheiko G, Agarwal K. Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England. Am J Gastroenterol 2022. [PMID: 36191276 DOI: 10.14309/ajg.0000000000002041] [Reference Citation Analysis]
3 Beiser ME, Shaw LC, Wilson GA, Muse KO, Shores SK, Baggett TP. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020. J Gen Intern Med 2022. [PMID: 36127534 DOI: 10.1007/s11606-022-07778-w] [Reference Citation Analysis]
4 Jacka BP, Bazerman LB, Dickerson C, Moody M, Martin J, Patry E, Cady T, Compere H, Boudreau M, Beckwith CG. Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges. International Journal of Drug Policy 2022;103:103668. [DOI: 10.1016/j.drugpo.2022.103668] [Reference Citation Analysis]
5 Nephew LD, Wang Y, Mohamed K, Nichols D, Rawl SM, Orman E, Desai AP, Patidar KR, Ghabril M, Chalasani N, Kasting ML. Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist. J Viral Hepat 2022;29:366-74. [PMID: 35254695 DOI: 10.1111/jvh.13661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Romagnoli D. Elimination of hepatitis C virus infection in Europe: targeting the obstacles. Exploration of Medicine. [DOI: 10.37349/emed.2022.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Murayama A, Momose H, Yamada N, Matsubayashi K, Muramatsu M, Hamaguchi I, Kato T. Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection. Front Cell Infect Microbiol 2022;11:793472. [DOI: 10.3389/fcimb.2021.793472] [Reference Citation Analysis]
8 Bs RM, Wong K, Naylor P, Ehrinpreis M, Mutchnick M. Racial disparity in age and genotype defines urban hepatitis C patient profiles in the recent direct-acting antiviral era. GHOA 2021;12:190-197. [DOI: 10.15406/ghoa.2021.12.00485] [Reference Citation Analysis]